Advertisement

Response to the Consensus Statement of the PTSD Psychopharmacology Working Group

Published:November 22, 2017DOI:https://doi.org/10.1016/j.biopsych.2017.11.023
      We are writing in response to the letter to the editor by Krystal et al. (
      • Krystal J.H.
      • Davis L.L.
      • Neylan T.C.
      • A Raskind M.
      • Schnurr P.P.
      • Stein M.B.
      • et al.
      It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: A consensus statement of the PTSD Psychopharmacology Working Group.
      ). This timely research statement pointed out some of the barriers to translating a wealth of posttraumatic stress disorder (PTSD) research into effective pharmacological strategies. The group did not review all potential agents currently being assessed for PTSD; thus, the addition of two promising candidates—cannabis and 3,4-methylenedioxymethamphetamine (MDMA)—would make this report more comprehensive. Both are under investigation in U.S. Food and Drug Administration (FDA)–regulated phase 2 clinical trials for PTSD sponsored by the nonprofit organization, the Multidisciplinary Association for Psychedelic Studies (MAPS).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Krystal J.H.
        • Davis L.L.
        • Neylan T.C.
        • A Raskind M.
        • Schnurr P.P.
        • Stein M.B.
        • et al.
        It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: A consensus statement of the PTSD Psychopharmacology Working Group.
        Biol Psychiatry. 2017; 82: e51-e59
        • Raharjo T.J.
        • Verpoorte R.
        Methods for the analysis of cannabinoids in biological materials: A review.
        Phytochem Anal. 2004; 15: 79-94
        • Russo E.
        • Guy G.W.
        A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.
        Med Hypotheses. 2006; 66: 234-246
        • Russo E.B.
        Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
        Br J Pharmacol. 2011; 163: 1344-1364
        • Mithoefer M.C.
        • Wagner M.T.
        • Mithoefer A.T.
        • Jerome L.
        • Doblin R.
        The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study.
        J Psychopharmacol. 2011; 25: 439-452
        • Mithoefer M.C.
        • Wagner M.T.
        • Mithoefer A.T.
        • Jerome L.
        • Martin S.F.
        • Yazar-Klosinski B.
        • et al.
        Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study.
        J Psychopharmacol. 2013; 27: 28-39
        • Oehen P.
        • Traber R.
        • Widmer V.
        • Schnyder U.
        A randomized, controlled pilot study of MDMA (+/- 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD).
        J Psychopharmacol. 2013; 27: 40-52
        • Diazgranados N.
        • Ibrahim L.
        • Brutsche N.E.
        • Newberg A.
        • Kronstein P.
        • Khalife S.
        • et al.
        A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
        Arch Gen Psychiatry. 2010; 67: 793-802
        • Zarate Jr., C.A.
        • Singh J.B.
        • Carlson P.J.
        • Brutsche N.E.
        • Ameli R.
        • Luckenbaugh D.A.
        • et al.
        A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
        Arch Gen Psychiatry. 2006; 63: 856-864
        • Murrough J.W.
        • Iosifescu D.V.
        • Chang L.C.
        • Al Jurdi R.K.
        • Green C.E.
        • Perez A.M.
        • et al.
        Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial.
        Am J Psychiatry. 2013; 170: 1134-1142

      Linked Article

      • It Is Time to Address the Crisis in the Pharmacotherapy of Posttraumatic Stress Disorder: A Consensus Statement of the PTSD Psychopharmacology Working Group
        Biological PsychiatryVol. 82Issue 7
        • Preview
          There is an urgent need to address a critical lack of advancement in the psychopharmacologic treatment of posttraumatic stress disorder (PTSD). The clinical, social, and financial burden of ineffectively treated PTSD is enormous (1–6). The impact of PTSD morbidity and mortality is further magnified by its substantial disruptions in family, workplace, and societal contexts (7). For the Department of Veterans Affairs (VA) and Department of Defense (DoD), i.e., institutions that are vehicles for the expression of the national debt to military personnel who developed PTSD as a consequence of their military service, the need to help these people has taken on significant priority.
        • Full-Text
        • PDF